Misha Dagan

Misha Dagan

Auto-generated profile, based on publicly available information

Misha Dagan

Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne, Victoria 3004

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JSJulia Stehli
Julia Stehli
DDDiem Dinh
Diem Dinh
MDMisha Dagan
Misha Dagan
SDStephen J. Duffy
Stephen J. Duffy
ABAngela Brennan
Angela Brennan
SZSarah Zaman
Sarah Zaman
Background: Women with ST‐segment–elevation myocardial infarction experience delays in reperfusion compared with men with little data on each time component from symptom onset to reperfusion. This study analyzed sex discrepancies in patient delays, prehospital system delays, and hospital delays. Methods and Results: Consecutive patients with ST‐segment–elevation myocardial infarction treated with percutaneous coronary intervention across 30 hospitals in the Victorian Cardiac Outcomes Registry (2013–2018) were analyzed. Data from the Ambulance Victoria Data warehouse were used to perform linkage to the Victorian Cardiac Outcomes Registry for all patients transported via emergency medical services (EMS). The primary end point was EMS call‐to‐door time (prehospital system delay). Secondary end points included symptom‐to‐EMS call time (patient delay), door‐to‐device time (hospital delay), 30‐day mortality, major adverse cardiovascular events, and major bleeding. End points were analyzed according to sex and adjusted for age, comorbidities, cardiogenic shock, cardiac arrest, and symptom onset time. A total of 6330 (21% women) patients with ST‐segment–elevation myocardial infarction were transported by EMS. Compared with men, women had longer adjusted geometric mean symptom‐to‐EMS call times (47.0 versus 44.0 minutes; P <0.001), EMS call‐to‐door times (58.1 versus 55.7 minutes; P <0.001), and door‐to‐device times (58.5 versus 54.9 minutes; P =0.006). Compared with men, women had higher 30‐day mortality (odds ratio [OR], 1.38; 95% CI, 1.06–1.79; P =0.02) and major bleeding (OR, 1.54; 95% CI, 1.08–2.20; P =0.02). Conclusions: Female patients with ST‐segment–elevation myocardial infarction experienced excess delays in patient delays, prehospital system delays, and hospital delays, even after adjustment for confounders. Prehospital system and hospital delays resulted in an adjusted excess delay of 10 minutes compared with men.

19 November 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LDLuke P. Dawson
Luke P. Dawson
DCDavid Chen
David Chen
MDMisha Dagan
Misha Dagan
JBJason Bloom
Jason Bloom
ATAndrew Taylor
Andrew Taylor
DSDion Stub
Dion Stub
The timing of oral P2Y12 inhibitor administration in patients with non-ST elevation acute coronary syndromes (NSTEACS) has been a matter of substantial debate over the last 2 decades.1-4 Pretreatment, defined as oral P2Y12 inhibitor administration prior to angiography and usually at the time of diagnosis, has been commonly used with the rationale that there may be greater platelet inhibition at time of percutaneous coronary intervention (PCI); there may be reduced ischemic events while awaiting angiography; and more potent antiplatelet agents, such as glycoprotein IIb/IIIa inhibitors, may be avoided.4 While these reasons may be logical, there are limited data to support this approach. Previous guidelines supporting a pretreatment strategy relied mostly on older and indirect data,5,6 and the most recent comprehensive meta-analysis (performed in 2014), which did not support pretreatment, relied mostly on observational rather than randomized data.1,7 Arguments against pretreatment mainly relate to increased bleeding risk among patients who require PCI, in addition to those who need coronary artery bypass grafting (in whom surgery may be delayed with increased risk of postoperative bleeding) and those who may have an alternate diagnosis (eg, aortic dissection). European guidelines recently changed to recommend against pretreatment in patients with NSTEACS based on several trials and observational studies.8-12 However, debate still remains regarding the optimal approach,13 and several further trials have been published that allow for a more comprehensive pooled systematic review.

2 December 2022 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
JSJulia Stehli
Julia Stehli
RJRozanne Johnston
Rozanne Johnston
SDStephen J Duffy
Stephen J Duffy
SZSarah Zaman
Sarah Zaman
TGTomoe D H Gusberti
Tomoe D H Gusberti
AWAntony Walton
Antony Walton
Aims: Increasing transcatheter aortic valve implantation (TAVI) rates have resulted in prolonged waiting times. These have been associated with heart failure hospitalizations (HFH) and mortality yet sex differences have not yet been reported. Methods and results: All patients who underwent TAVI for severe aortic stenosis at a tertiary referral hospital in Australia were prospectively included. Total waiting time was divided into ‘work-up’ waiting time (period from referral date until heart team approval) and, ‘procedural’ waiting time (period from heart team approval until procedure date). Patients were analysed according to sex. Cohorts were matched to correct for differences in baseline and procedural variables. The primary endpoints were waiting times. Secondary outcomes included a composite of 30-day mortality and HFH, quality of life, and mobility. A total of 407 patients (42% women) were included. After matching of the two cohorts (345 patients), women had significantly longer total waiting times than men: median 156 [interquartile range (IQR) 114–220] days in women vs. 147 [IQR 92–204] days in men (P = 0.037) including longer work-up (83 [IQR 50–128] vs. 71 [IQR 36–119], P = 0.15) and procedural waiting times (65 [IQR 44–100] vs. 58 [IQR 30–93], P = 0.042). Increasing waiting times were associated with higher 30-day mortality and HFH (P = 0.01 for work-up waiting time, P = 0.02 for procedural waiting time) and decreased 30-day mobility (P = 0.044 for procedural waiting time) in women, but not in men. Conclusion: TAVI waiting times are significantly longer in women compared to men and are associated with increased mortality and HFH and reduced mobility at 30-days.

4 February 2021 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
MDMisha Dagan
Misha Dagan
DDDiem T Dinh
Diem T Dinh
JSJulia Stehli
Julia Stehli
CTChristianne Tan
Christianne Tan
ABAngela Brennan
Angela Brennan
SDStephen J Duffy
Stephen J Duffy
We sought to investigate if sex disparity exists for secondary prevention pharmacotherapy following acute coronary syndrome (ACS) and impact on long-term clinical outcomes. We analysed data on medical management 30-day post-percutaneous coronary intervention (PCI) for ACS in 20 976 patients within the multicentre Melbourne Interventional Group registry (2005–2017). Optimal medical therapy (OMT) was defined as five guideline-recommended medications, near-optimal medical therapy (NMT) as four medications, sub-optimal medical therapy (SMT) as ≤3 medications. Overall, 65% of patients received OMT, 27% NMT and 8% SMT. Mean age was 64 ± 12 years; 24% (4931) were female. Women were older (68 ± 12 vs. 62 ± 12 years) and had more comorbidities. Women were less likely to receive OMT (61% vs. 66%) and more likely to receive SMT (10% vs. 8%) compared to men, P < 0.001. On long-term follow-up (median 5 years, interquartile range 2–8 years), women had higher unadjusted mortality (20% vs. 13%, P < 0.001). However, after adjusting for medical therapy and baseline risk, women had lower long-term mortality [hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.79–0.98; P = 0.02]. NMT (HR 1.17, 95% CI 1.05–1.31; P = 0.004) and SMT (HR 1.79, 95% CI 1.55–2.07; P < 0.001) were found to be independent predictors of long-term mortality. Women are less likely to be prescribed optimal secondary prevention medications following PCI for ACS. Lower adjusted long-term mortality amongst women suggests that as well as baseline differences between gender, optimization of secondary prevention medical therapy amongst women can lead to improved outcomes. This highlights the need to focus on minimizing the gap in secondary prevention pharmacotherapy between sexes following ACS.

1 January 2021 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
MDMisha Dagan
Misha Dagan
TYTimothy Yeung
Timothy Yeung
JSJulia Stehli
Julia Stehli
DSDion Stub
Dion Stub
AWAntony S. Walton
Antony S. Walton
SDStephen J. Duffy
Stephen J. Duffy

11 November 2022 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
JSJulia Stehli
Julia Stehli
MDMisha Dagan
Misha Dagan
SDStephen J. Duffy
Stephen J. Duffy
SMStéphane Morisset
Stéphane Morisset
PVPieter Adriaan Vriesendorp
Pieter Adriaan Vriesendorp
AWAntony S. Walton
Antony S. Walton